ProQR Therapeutics nominated Dr. Lykke Hinsch Gylvin to its Board of Directors, subject to shareholder approval at the upcoming Annual General Meeting.
Key takeaways
Dr. Lykke Hinsch Gylvin, CMO of Boehringer Ingelheim, nominated to ProQR's Board.
Nomination requires shareholder approval at the upcoming Annual General Meeting.
If appointed, she will serve as an independent non-executive director.
Her expertise in global drug development supports ProQR's pipeline advancement.